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Abstract
Background: Rhabdomyosarcoma (RMS) is the most commonly diagnosed malignant soft tissue tumour in children
and adolescents. Aberrant expression of Anaplastic Lymphoma Kinase (ALK) and MET gene has been implicated in the
malignant progression of RMS, especially in the alveolar subtype. This observation suggests that crizotinib (PF-02341066),
a kinase inhibitor against ALK and MET, may have a therapeutic role in RMS, although its antitumour activity in
this malignancy has not yet been studied.
Methods: RH4 and RH30 alveolar RMS (ARMS) cell lines were treated with crizotinib and then assessed by using
proliferation, viability, migration and colony formation assays. Multiple approaches, including flow cytometry,
immunofluorescence, western blotting and siRNA-based knock-down, were used in order to investigate possible
molecular mechanisms linked to crizotinib activity.
Results: In vitro treatment with crizotinib inhibited ALK and MET proteins, as well as Insulin-like Growth Factor 1
Receptor (IGF1R), with a concomitant robust dephosphorylation of AKT and ERK, two downstream kinases involved in
RMS cell proliferation and survival. Exposure to crizotinib impaired cell growth, and accumulation at G2/M phase was
attributed to an altered expression and activation of checkpoint regulators, such as Cyclin B1 and Cdc2. Crizotinib was
able to induce apoptosis and autophagy in a dose-dependent manner, as shown by caspase-3 activation/PARP
proteolytic cleavage down-regulation and by LC3 activation/p62 down-regulation, respectively. The accumulation
of reactive oxygen species (ROS) seemed to contribute to crizotinib effects in RH4 and RH30 cells. Moreover,
crizotinib-treated RH4 and RH30 cells exhibited a decreased migratory/invasive capacity and clonogenic potential.
Conclusions: These results provide a further insight into the molecular mechanisms affected by crizotinib in
ARMS cells inferring that it could be a useful therapeutic tool in ARMS cancer treatment.
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Background
Rhabdomyosarcoma (RMS) is the most common malig-
nant soft tissue tumour in childhood, representing
approximately 50 % of all sarcomas and 4–5 % of malig-
nant solid tumours in children aged 0–14 years [1, 2].
The two major histological subtypes, alveolar rhabdo-
myosarcoma (ARMS) and embryonal rhabdomyosar-
coma (ERMS), differ in prevalence, body location,
clinical features and outcome [3]. ARMS generally carries
either t(2;13)(q35,q14) or t(1;13)(p36;q14) translocations,
which generate PAX3/FOXO1 and PAX7/FOXO1 fusion
proteins, respectively [4, 5], whilst a wide range of genetic
aberrations, including loss of heterozygosity at 11p15.5
[6], have been identified in ERMS. Even gene expression
profiles widely differ in ARMS and ERMS tumours [7].
Recent studies have demonstrated aberrant ALK
(anaplastic lymphoma kinase) expression especially in
PAX3/7-FOXO1-positive ARMS samples [8–11]. ALK
is a member of the insulin receptor family of receptor
tyrosine kinases (RTKs) and is up-regulated during
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embryonic development of the nervous system, being
maintained at low levels in adult tissues [12]. MET, an-
other RTK normally activated in development and tis-
sue regeneration [13], was found to be highly expressed
in RMS cell lines [14]. Aberrant expression, amplifica-
tion, translocations or mutations involving ALK and
MET genes have an important role in driving tumouri-
genesis through the activation of multiple pathways, in-
cluding the PI3K/AKT signalling cascade, which
controls many cellular functions including survival,
proliferation, differentiation, adhesion and migration
[11–18]. Several studies have reported that ALK or
MET over-expression and constitutive kinase activation
correlate with advanced stage and may be predictive of
poor clinical outcome in several neoplasia, such as
neuroblastoma, gastrointestinal carcinoma and non-small-
cell lung cancer [19–23]. Crizotinib (PF-02341066) is a
small molecule initially identified as a highly potent inhibi-
tor of ALK and MET receptor tyrosine kinases [24, 25].
Subsequent studies have shown that crizotinib is also able
to block the activation of other RTKs involved in tumour
development/progression, such as ROS1 and PDGFR-
alpha [26, 27]. The antitumour activity of crizotinib in
cancer clinical trials has been significant [25, 28], leading
to the Food and Drug Administration (FDA) approval as
an integral addition to clinical treatment of patients with
non-small cell lung cancer (NSCLC) carrying ALK trans-
locations [29, 30]. More recently, crizotinib has also been
proposed as a promising drug in soft tissue sarcomas [28],
but the possible activity in RMS has not yet been
elucidated.
Since ALK/MET-positive RMSs may be sensitive to
ALK/MET tyrosine kinase inhibitors, the present study
investigated whether crizotinib was able to abolish the
oncogene-dependent signalling by affecting proliferation
and survival in this subset of RMS. RH4 and RH30, two
human ARMS cell lines harbouring PAX3-FOXO1
translocation, and with raised ALK and MET expression
[11, 14], were treated with crizotinib to evaluate the
effects on cell proliferation, apoptosis, autophagy, colony
formation ability and cell cycle as well as on several spe-
cific molecular pathways. Incubation with crizotinib re-
sulted in a dose-dependent reduction in tumour cell
growth, with a clear arrest in G2/M phase and - using
high concentrations (i.e. 5 μM) - a pronounced apoptosis
and autophagy. Crizotinib blocked the activation of
ALK, MET and IGF1R, with a concomitant inhibition of
the downstream mediator AKT, whose constitutive
phosphorylation is associated with malignant transform-
ation and poor outcome in RMS [31]. This study is the
first to describe the in vitro activity of crizotinib in RMS
tumours, this suggesting that this molecule may be a po-
tential therapeutic agent that effectively controls ARMS
growth by inhibiting ALK, MET and IGF1R pathways.
Methods
Compound
Crizotinib, also known as PF-02341066, was supplied
as lyophilized powder by Cell Signalling Technology
(Danvers, MA) and reconstituted in dimethyl sulfox-
ide (DMSO, Sigma, St. Louis, MO) to a final concen-
tration of 2 mM. Aliquots were conserved at −20 °C.
Human recombinant IGF1 was purchased as lyophi-
lized powders (PeproTech EC Ltd, UK) and reconsti-
tuted in sterile deionised H2O and stored in aliquots
at −20 °C.
Cell cultures
Human ARMS (RH4 and RH30) and ERMS (RD and
RD18) cells [32, 33] were cultured in complete medium,
i.e. DMEM-HG (Carlsbad, CA), supplemented with 10 %
Foetal Bovine Serum (FBS) (Gibco), 2 mM L-glutamine
(Gibco), 100 IU/mL penicillin and 100 μg/ml strepto-
mycin (Gibco). All cell lines were maintained at 37 °C in
5 % CO2.
Tumour samples
Six RMS tumour samples, 3 ARMSs and 3 ERMSs, were
obtained at diagnosis before any treatment from children
admitted to the Department of Oncology at Alder Hey
Children’s NHS Trust, Liverpool. Histopathological diag-
nosis was confirmed using immunohistochemistry. ARMS
were investigated for PAX3/7-FOXO1 translocations using
standard FISH analysis, and all were positive. Institutional
written informed consent was obtained from the patient’s
parents or legal guardians. The study underwent ethical
review and approval according to the local institutional
guidelines (Alder Hey Children’s NHS Foundation Trust
Ethics Committee, approval number 09/H1002/88).
RNA extraction and RT-PCR
Total RNA was isolated from the four cell lines using
TRIzol reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. One microgram of total
RNA was reverse transcribed using the High Capacity
cDNA Reverse Transcription Kit (Life Technologies,
Carlsbad, CA, USA). PCR was conducted as previously
described [9]. Subsequent PCR reactions were performed
with gene-specific primers, designed from the human
ALK (ALK forward 5′-GCTGAGCAAGCTCCGCACC
TCGAC-3′ and ALK reverse 5′-CCCGCCATGAGCTCC
AGCAGGATG-3′) and MET (MET forward 5′-GAGCG
CTTTGTGAGCAGATG-3′ and MET reverse 5′-AAC
CAGTGGAGAAGTCAGCG- 3′) exonic sequences. GAP
DH housekeeping gene was used as control. RT-PCR
products were resolved on a 1.5 % agarose gel.
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Cell proliferation assays
RH4 and RH30 cell proliferation was measured using
the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide (MTT) assay. RH4 and RH30 cells (5×103) were
seeded in sexuplicates into 96-well plates 24 h before
treatment with crizotinib at concentrations ranging from
0.01 to 5 μM. Control cells were treated with DMSO at
the maximum amount used to deliver crizotinib. Treat-
ment medium was replaced every day with a medium
containing a fresh drug dilution. At 72 h of crizotinib
exposure, 0.5 mg/ml MTT solution was added to each
well for 3 h. After incubation, 200 μl of DMSO were
added to each well and mixed thoroughly. Absorbance
was measured at 540 nm, with a reference wavelength of
630 nm, using a plate reader and the readings were
plotted as a mean of ODtreatment/ODcontrol ± standard
deviation (SD).
For cell number count, RH4 and RH30 cells were
seeded onto 12-well plates and treated with 1.5 μM
crizotinib or 0.075 % DMSO for 72 h. Direct counting of
living cells was performed by labelling cells with trypan
blue (1:1) exclusion dye (Sigma). Trypan blue-negative
cells were regarded as viable cells.
Cell cycle analysis
RH4 and RH30 cells were incubated in 6-well cell
culture plates overnight to allow cell adhesion. After
incubation, cells were treated for 24, 48 or 72 h with
1.5 μM or 5 μM crizotinib. At the end of each treatment,
cells were trypsinised, washed with PBS, fixed in 75 %
ice-cold ethanol and stored overnight at 4 °C. Cells were
washed with PBS, treated with 100 μg/mL RNAse A for
30 min at 37 °C and then stained with 50 μg/mL Propi-
dium Iodide (PI) solution. Samples subjected to flow
cytometric analysis were loaded into a BD FACSCalibur
(BD Biosciences, Franklin Lakes, NJ) and PI fluorescence
was detected in FL2 with active Double Discrimination
Module using CellQuest Pro (BD Biosciences). DNA cell
cycle analysis of flow cytometric data was carried out
using the software ModFit LT 3.0 (Verity Software
House). Three independent experiments were performed
for each treatment.
Morphological assessment of crizotinib-treated cells
An inverted phase contrast microscope was used to
observe the morphological changes of the cells treated
or untreated with 1.5 μM crizotinib. After being cultured
for 48 h, cells were stained by the standard Giemsa
method. Briefly, cells were fixed by cold methanol for
5 min and stained in 10 % Giemsa solution (Sigma) for
15 min at RT. After rinsing in tap water, cells were air-
dried and photographed under a light microscope at 40×
magnification. The nuclei were stained blue/violet.
Apoptosis analysis
Apoptosis was analysed by flow cytometry using PE
Annexin V Apoptosis Detection Kit I (BD Biosciences).
Briefly, RH4 and RH30 cells were seeded overnight in
6-well plate and treated with crizotinib for 48 h at
1.5 μM or 5 μM. Control cells were treated with DMSO
at the maximum amount used to deliver crizotinib.
DMSO had no toxic effects on RH4 and RH30 cell lines
in total cell count experiments with culture media only,
DMSO only and crizotinib (data not shown). Floating
and attached cells were collected, washed twice in cold 1×
Annexin V Binding Buffer and suspended in 1× Annexin
V Binding Buffer at 106 cells/ml. Approximately 105 cells
were stained with Annexin V and 7-Amino-Actinomycin
(7-AAD) for 15 min at RT in the dark according to the
manufacturer’s instructions. Annexin V and 7-AAD fluor-
escence intensities of control or treated samples were ana-
lysed using a BD FACSCalibur (BD Biosciences). Data
were collected analysed using Cell Quest Pro software
(BD Biosciences).
Caspases-3/7 activities were measured using Caspase-
glo 3/7 kit assay (Promega, Madison, WI, USA). Briefly,
RH4 and RH30 cells were seeded overnight in a 96-well
plate and treated with crizotinib at 0–1.5–5 μM. After
48 h, 100 μl of Caspase-glo 3/7 reagent were added to
each well and cells were incubated in the dark for 1 h at
RT. Luminescence was read in a Glomax luminometer
(Promega) and results were expressed as fold change of
caspase 3/7 activity to respective control cells.
Migration and invasion assays
RH4 and RH30 cells (5×104 in 24-well plates) were
treated in complete medium with 1.5 μM crizotinib or
with DMSO, as a control, for 24 h before plating into BD
FalconTM Cell Culture Inserts (Corning, Tewksbury, MA).
Chambers with cells contained medium without serum,
whilst the lower well had DMEM supplemented with 10 %
FBS, used as chemo-attractant. After 24 h, cells which had
not migrated were removed by swabbing, whilst the
migrated cells at the base of the inserts were fixed in 100 %
methanol and stained with 0.1 % crystal violet dye.
For tumour invasion assay, RH4 and RH30 cells
(5×104 in 24-well plates) treated with or without 1.5 μM
crizotinib for 24 h were plated into Matrigel-coated
chambers (BD Biosciences). Medium in the upper cham-
ber was supplemented without FBS, while FBS concen-
tration was 10 % in the lower chamber. After 24 h, the
non-invasive cells on the upper surface of the membrane
were removed with a cotton swab, whilst cells able to
invade through the Matrigel matrix and attached to the
lower surface of the chamber were fixed and stained
with crystal violet.
Cells were photographed under a light microscope at
20× magnifications; 8 randomly selected fields were
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examined and counted. The average number of migrated
cells was calculated.
Soft agar assay
For anchorage-independent colony formation assays,
2 ml of 0.7 % low-melting agarose in DMEM-HG with
10 % FBS were poured into 6-well plates. Subsequently,
2 ml of top agar consisting of 0.35 % low-melting
agarose in complete medium, 3×104 cells and 1.5 μM
crizotinib or DMSO were added to each well. After
solidification, each well was covered with 1 ml of culture
medium (in the presence or absence of crizotinib), which
was refreshed every 3 days. Cells were allowed to grow
at 37 °C and 5 % CO2. After 21 days, colonies were
stained with 0.05 % crystal violet for 1 h and photo-
graphed under an inverted light microscope. Colonies
which exceed an arbitrary size ≥ 50 μm in diameter were
counted in drug-treated and mocked-control cultures.
Colony formation assay
For anchorage-dependent colony formation assays, RH4
and RH30 were plated in 6-well plates at 5×103 cells/
well. After 24 h, 1.5 μM crizotinib or DMSO were added
to the wells. Cells were cultured in the presence or ab-
sence of crizotinib for 8 days and then colonies were vi-
sualized by light microscopy. Colonies which exceed an
arbitrary size ≥ 50 μm in diameter were counted in drug-
treated cultures relative to mocked-control cultures.
Immunoprecipitation and western blotting
RH4 and RH30 cells were plated in 6-well plates (4×105
cells/well) and grown overnight to allow cell adhesion.
Cells were treated for 24 h with 1.5 μM crizotinib and
then lysed in RIPA buffer (50 mM Tris–HCl pH 7.4,
150 mM NaCl, 1 mM EDTA, 1 % NP-40, 1 mM PMSF,
50 mM NaF, 1 mM Na3VO4, and 1× protease inhibitors)
for 20 min. Samples were cleared at 14,000 rpm for
10 min and quantified using the Biorad Protein Assay Kit
(Biorad, Berkeley, CA). For immuniprecipitation, total
proteins (800 μg) were extracted with IP-buffer (25 mM
Hepes, 400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA,
0.5 % Triton-X, 3 mM DTT, 1 mM Na3VO4, 1 mM PMSF,
1× protease inhibitors) and incubated with primary anti-
body (2.5 μg) overnight at +4 °C. A/G-conjugated agarose
beads (Santa Cruz Biotechnology, Dallas, TX) were added
and incubated for 2 h at 4 °C. Immunocomplexes were
washed 3 times with IP-buffer. For Western blotting, total
protein extracts (30–100 μg) were resolved on 8–15 %
SDS-PAGE gels and transferred onto PVDF membranes
(Merck Millipore, Guyancourt, F). Blots were blocked in
5 % not-fat milk or BSA and incubated over-night at +4 °C
with the following primary antibodies: phospho (p)-ALK
(1:500), p-MET (1:500), p-ERK (1:3000), p-AKT (1:2000),
p-IGF1R (1:1000), ALK-XP (1:2000), AKT (1:2000), ERK
(1:2000), IGF1R (1:1000), cleaved caspase-3 (1:200),
cleaved PARP (1:1000) by Cell Signalling Technology;
MET (1:1000), Cyclin B1 (1:1000), Cyclin D3 (1:250),
p-Cdc2 (1:300), Cdc25A (1:1000), Cdc25C (1:1000),
p27 (1:500) and Cdk4 (1:1000) by Santa Cruz Biotech-
nology; p62/sequestosome 1 (1:1000, BD Biosciences);
LC3 (1:1000, Sigma). Antibody against tubulin (1:20000,
Sigma) was used as a loading control. Membranes were
then incubated in appropriate horseradish peroxidase-
conjugated secondary antibodies (1:4000 dilution, Santa
Cruz Biotechnology). Protein signals were detected using
WesternBright ECL kit (Advansta, Menlo Park, CA),
according to the manufacturer’s instructions, and visual-
ized by ChemiDoc XRS+ (Bio-Rad, Texas, US).
Immunofluorescence
RH4 and RH30 cells (104), plated on coverslips into 24-well
plates, were allowed to attach overnight and then incubated
for 24 h in the presence of 1.5 μM crizotinib or DMSO, as
control, at 37 °C. Cells were fixed in 4 % paraformaldehyde
(PFA) in PBS for 30 min at RT, followed by treatment with
0.1 M glycine in PBS for 20 min at RT and with 0.1 %
Triton X-100 in PBS for additional 5 min at RT to allow
permeabilization. Cells were incubated with primary anti-
bodies against p21, Cdc25C, Cyclin B1, Cdc2 or p-Cdc2
(1:20 dilution in PBS; Santa Cruz Biotechnology) for 1 h at
RT. After washing in PBS, cells were incubated with appro-
priate FITC-conjugated or Texas Red-conjugated secondary
antibodies (1:200 dilution in PBS; Jackson Immunoresearch,
West Grove, PA) for 30 min at RT in the dark. Nuclei were
stained with using 4′, 6-diamido-2-phenylindole dihy-
drochloride (DAPI) (1:10000 in PBS; Sigma). TRITC-
phalloidin (Sigma), identifying filamentous actin of the
cellular cytoskeleton, was used at 1:50 dilution in PBS. The
single-stained and merged images were acquired with
Zeiss ApoTome and Axiovision software (Carl Zeiss,
Jena, Germany) using a 40× magnification.
To monitor microtubule dynamics, cells were treated
with 1.5 μM crizotinib or 50 ng/ml nocodazole, as posi-
tive control. Cells were fixed after 4 h, stained with anti-
alpha-tubulin (1:2000 in PBS; Sigma)/FITC-anti-mouse
antibody.
For assessment of the Annexin V-FITC/PI staining in
apoptotic cells, RH4 and RH30 cells, plated on coverslips
and treated with crizotinib (1.5 and 5 μM) for 48 h, were
washed with 1× binding buffer and incubated with
Annexin V-FITC and PI for 15 min at RT in the dark.
Cells were fixed in 4 % PFA in 1× binding buffer for
30 min at RT, followed by 1× binding buffer washing for
three times. Control cells were treated with DMSO at
the maximum amount used to deliver crizotinib.
All the single-stained and merged images were ac-
quired with Zeiss ApoTome and Axiovision software
(Carl Zeiss, Jena, Germany) using a 40× magnification.
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Detection of reactive oxygen species (ROS)
The accumulation of ROS in RH4 and RH30 cells was
determined using the general oxidative stress indicator
H2DCFDA that fluoresces upon oxidation. Cells, treated
with crizotinib (1.5 and 5 μM) for 24 h, were incubated
at 37 °C in medium containing 5 μM H2DCFDA (Sigma).
Control cells were treated with DMSO at the maximum
amount used to deliver crizotinib. After 40 min, cells were
washed with PBS and fluorescent intensity was detected
by FACSCalibur in FL-1 channel. In some experiments,
cells were pre-incubated with or without NAC (5 mM) for
1 h, and then treated with or without crizotinb for 24 h,
followed by loading with 5 μM of H2DCFDA.
siRNA transfection
ALK and MET siRNA (Ambion) were transfected into
RH4 and RH30 cells with RNAiMax (Invitrogen) accord-
ing to the manufacturer’s instructions. Negative Control
(NC) siRNA (Ambion), having no significant sequence
similarity to mouse, rat, or human gene sequences, was
used as in mocked-control cells. Forty-eight hours after
transfection, cells were submitted to different molecular
techniques for further analysis.
Statistical analysis
Statistical significance was assessed by Student’s t-tests
and probability (p) values of less than 0.05 were accepted
as significant. All the experiments were done in triplicates
and repeated three times unless mentioned otherwise.
Results
ALK and MET are differentially expressed in human ARMS
vs. ERMS cell lines and tumour samples
The ALK and MET expression at mRNA and protein
levels in two ARMS (RH4 and RH30) and two ERMS (RD
and RD18) cell lines was evaluated. RT-PCR experiments
showed that ARMS samples had a marked expression of
ALK and MET transcripts in comparison to ERMS cells
(Fig. 1a). Western blotting analysis showed higher levels of
both total ALK and MET proteins in RH4 and RH30 cells
than in RD and RD18 cells (Fig. 1b). ALK protein was
detected as both an approximately 200 kDa band, reflect-
ing the full-length form, and a second band of about
140 kDa (Fig. 1b), which may represents a splice variant
or a degraded product of ALK [33]. Similarly, activation of
ALK and MET proteins (p-ALK and p-MET) was evident
only in ARMS cells (Fig. 1b) even if basal phosphorylation
of ALK receptor was weakly detectable in accordance with
its recently demonstrated susceptibility to intracellular
phosphatases [11]. RT-PCR analysis performed in a panel
of 6 RMS tumours (3 ARMSs and 3 ERMSs) confirmed
that ALK and MET mRNAs are expressed at significantly
higher levels in ARMS compared to ERMS (Fig. 1c).
Taken together, these data suggest that ALK and MET
expression is up-regulated in ARMS.
Crizotinib inhibits cell proliferation and viability in ARMS
cell lines
Since significant ALK and MET expression was only
detected in ARMS samples, the effect of crizotinib, an
ATP competitive, MET and ALK inhibitor, was evaluated
on the growth of RH4 and RH30 ARMS cell lines. Cells
were exposed for 72 h to increasing concentrations of
the drug, with values ranging from 0 to 5 μM. Cell
growth and viability were clearly inhibited in a dose-
dependent manner, with IC50 values of about 1.5 μM
(Fig. 2a), which are within the range of clinical relevance
[25]. Direct counting for living cells using the trypan
blue dye exclusion test confirmed that crizotinib induced
a significant reduction in cell number (Fig. 2b).
Crizotinib inhibits cell growth and modulates G1/S and
G2/M cell cycle signalling pathways in ARMS cell lines
To further determine whether the crizotinib-dependent
decrease in ARMS cell growth was due to alterations
in cell cycle progression, flow cytometry analysis was
performed in RH4 and RH30 cells treated with or with-
out crizotinib. Based on propidium iodide staining of
cellular DNA content, almost all cells arrested in G2/
M phase (4n) when treated with 1.5 μM crizotinib with
a corresponding decrease of cell percentage in both G1
(2n) and S phases, while untreated cells rapidly divided
and progressed through the cell cycle at high rates
(Fig. 2c). Indeed, a high proportion of ARMS cells ac-
cumulated in G2/M after 24 h, with a maximum 4n-
peak at 48 h and the appearance of extra populations
of hyperdiploid cells (>4n) after 72 h of crizotinib-
exposure (data not shown). c (0.01, 0.5 and 1 μM) did
not significantly affect the cell cycle whilst higher cri-
zotinib concentrations (2.5 and 5 μM) profoundly in-
creased the number of G2/M phase cells and sub-G1
(apoptotic) population (data not shown), confirming a
dose-dependent G2/M cell growth arrest in both RH4
and RH30 cells.
Crizotinib exposure clearly affected the morphologic
appearance of both RH4 and RH30 cells, as confirmed
by Giemsa staining (Fig. 2d), with cells becoming larger,
less dense, and showing longer filaments in comparison
to mocked control cells. Moreover, crizotinib-treated
cells appeared multinucleated with evenly stained nu-
clear fragments (Fig. 2d).
To test the possible effect of crizotinib on microtubule
dynamics, ARMS cells were treated with crizotinib for
24 h and examined for spindle morphology by immuno-
fluorescence staining of alpha-tubulin (Fig. 2e). Normal
bipolar spindle formation was affected by crizotinib
treatment leading to multiple asters with unaligned
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chromosomes (Fig. 2e) and thus being responsible for
the formation of cells with an abnormal size and DNA
content. Nocodazole, a prototypic microtubule inhibitor,
was used as a positive control for microtubule depoly-
merisation (Fig. 2e).
To investigate the mechanism of the cell cycle pertur-
bations, the impact of crizotinib on the expression and
activation status of proteins related to the cell cycle
checkpoints was investigated. Western blotting experi-
ments showed that the crizotinib-related G2/M cell cycle
arrest was associated with an altered expression of Cyc-
lin B1, Cdc25C, p27 and Cdc2 phosphorylation at
Thr14/Tyr15 (the inactive form of Cdc2) in both RH4
and RH30 cells (Fig. 2f). Furthermore, crizotinib exposure
affected the expression of the G1/S cell cycle regulators
Cdc25A, CDK4 and Cyclin D3 (Fig. 2f). Immunofluores-
cence experiments confirmed that 1.5 μM crizotinib for
24 h caused over-expression and nuclear staining of p21, a
key regulator of cell cycle progression, and a cytoplasmatic
retention of Cdc25C, a protein involved in the mitosis
entry, in both RH4 and RH30 treated-cells (Fig. 3a-b). Fur-
thermore, ARMS cells exposed to crizotinib showed that
Cdc2 and Cyclin B1,two G2/M-regulating proteins, co-
localized outside the nuclear portion with a massive stain-
ing evident in the perinuclear area (Fig. 3a-b). This finding
suggested that the complex Cdc2/Cyclin B1 was not able
to enter into the nucleus, this leading to the G2/M arrest
assessed by FACS analysis. The marked up-regulation of
p-Cdc2 (Thr14/Tyr15) in both cell lines treated with cri-
zotinib confirmed that the Cdc2 protein was in its inactive
form (Fig. 3a-b). To our knowledge, this is the first experi-
mental evidence that links crizotinib with G2/M cell
cycle arrest and microtubules subcellular organization
in ARMS cells.
Crizotinib induces apoptosis in ARMS cell lines
The induction of apoptosis was investigated as another
possible mechanism by which crizotinib inhibits ARMS
cell growth. Treatment of RH4 and RH30 cell lines with
1.5 μM crizotinib for 48 h resulted in a moderate
increase in the percentage of cells undergoing early
(Annexin V positive; low right of the quadrants) and late
apoptosis/necrosis (Annexin V/7-AAD positive; upper
right of the quadrants) when compared to mock-treated
control cells, as assessed by flow cytometry (Fig. 4a).
Exposure to 5 μM crizotinib for the same time signifi-
cantly increased the number of RH4 and RH30 cells in
the late stages of apoptosis/necrosis (Fig. 4a). Annexin
V-FITC/PI dual staining confirmed that higher drug
concentrations caused drastic cytotoxic effects in both
ARMS cell lines (Fig. 4b). To address whether the apop-
totic process was associated with caspases, the effect of
crizotinib on caspase-3/7 proteolytic activity was studied.
Luminescence reading using the Caspase-glo 3/7 assay
showed that low doses of crizotinib led to moderate
levels of caspase 3/7 activation, whilst a more robust
activity was observed in response to higher drug concen-
trations (Fig. 4c). Western blotting experiments con-
firmed that cleaved PARP expression, the active form
involved in the apoptotic process, increased in concomi-
tance with crizotinib concentration (1.5 μM and 5 μM)
in both ARMS tumour cell lines, whilst cleaved caspase-
3 levels were evident only in 5 μM crizotinib-treated
cells (Fig. 4d). Taken together, the present data suggest
that crizotinib is able to induce apoptosis in RH4 and
RH30 cells via activation of the caspase cascade.
Crizotinib induces autophagy in ARMS cell lines by
increasing ROS accumulation
In order to evaluate whether crizotinib induced autoph-
agy in ARMS cells, the formation of autophagosomes
was investigated by staining with acridine orange (AO).
As shown in Fig. 5a, crizotinib treatment for 24 h in-
duced the accumulation of acidic vescicular organelles
(AVOs), which are linked to increased autophagy, in a
concentration-dependent manner in both RH4 and
Fig. 1 ALK and MET expression in RMS cell lines and tumour samples. a RT-PCR analysis showing the expression of ALK and MET mRNAs in RH4
and RH30, two ARMS cell lines, but faintly in RD and RD18, two ERMS cell lines. GAPDH expression used as the internal control. b Western blotting
experiments showing higher levels of both total ALK and MET proteins in ARMS than in ERMS cells. The activated forms of both ALK and MET
proteins were observed in ARMS samples using the specific p-ALK (Tyr1604) and p-MET (Tyr1234/Tyr1235) antibodies, respectively. Tubulin expression
was used as the internal control. c Expression of ALK and MET mRNAs measured by RT-PCR in a panel of ARMS and ERMS tumour samples
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RH30 cells. Crizotinib increased levels of LC3-II, a pro-
tein widely used for monitoring autophagy, with a
concomitant down-regulation of p62/sequestosome 1, a
protein involved in the formation and autophagic deg-
radation of polyubiquitin-containing bodies (Fig. 5b).
Taken together, these results demonstrate that elevated
doses of crizotinib are able to induce autophagy in
ARMS cells. Since autophagy is mediated by reactive
oxygen species (ROS) accumulation, the ability of crizo-
tinib to increase oxidative potential was monitored using
H2DCFDA fluorescent dye. ROS levels were evaluated
after crizotinib exposure in a concentration-dependent
manner in both RH4 and RH30 cell lines (Fig. 5c). Pre-
treatment for 1 h with NAC, a thiol antioxidant and
ROS scavenger, resulted in a significant reduction of
ROS levels after crizotinib addiction (data not shown),
further demonstrating the nature of the effect.
Crizotinib reduces cell migration and invasion ability as
well as anchorage-dependent and -independent growth
in ARMS cell lines
The assessment of the possible alteration of the migra-
tion capacity due to crizotinib in RH4 and RH30 was
carried out using a Boyden chamber assay. After 24 h, a
smaller number of cells were observed on the bottom
side of the membranes in crizotinib-treated cells when
compared with controls, indicating that the drug
reduced the ability of ARMS cells to migrate across the
pores of the Boyden membrane (Fig. 5d). Similarly,
crizotinib-treated ARMS cells were less able to invade
Matrigel (Fig. 5e). The effects of crizotinib on attachment-
independent clonal cell growth in a soft agar assay, a
hallmark of cell transformation were also analysed.
ARMS untreated cells were able to form colonies in an
anchorage-independent manner, while crizotinib dras-
tically reduced this ability, with both cell lines forming
smaller colonies (Fig. 5f). The capacity of crizotinib to
regulate cell growth was also tested on standard non-
pyrogenic polystyrene tissue culture plates for anchorage-
dependent (adherent) growth conditions. Highly malignant
untreated cells, plated at low concentration, were able to
survive, form colonies and proliferate, while crizotinib-
treated cells died 5 days after treatment (data not shown).
Crizotinib inhibits AKT and ERK phosphorylation in ARMS
cell lines
To gain insight into the molecular mechanisms under-
lying crizotinib effects on ARMS cells, ALK and MET
activation in treated RH4 and RH30 cells were firstly
evaluated. Phosphorylated levels of both ALK and MET
proteins were markedly reduced by crizotinib addition in
both cell lines, as revealed by immunoprecipitation
experiments with the appropriate antibody and the fol-
lowing hybridization with p-ALK (Tyr1604) and p-MET
(Tyr1234/Tyr1235), respectively (Fig. 6a). Similarly, the
expression of phospho-AKT (p-AKT) and phospho-ERK
(p-ERK), two important signalling molecules involved in
cancer cell growth and survival, was also evaluated in
RH4 and RH30 treated with 1.5 μM crizotinib for 24 h.
Crizotinib exposure led to a robust dephosphorylation
of AKT without affecting its total levels (Fig. 6b), whilst
p-ERK levels showed a less marked reduction (Fig. 6b).
Furthermore, the phosphorylation level of GSKβ and
P70S6K downstream molecules was substantially
reduced by crizotinb treatment (Fig. 6b), providing
evidence that this compound affects aberrant cell
signalling in ARMS cells by blocking AKT- and ERK-
related pathways.
To investigate the effect of suppressing ALK or MET
expression in RH4 and RH30 cells, we used specific
RNA duplexes directed against the ALK or MET coding
regions. A sequence against the C. elegans (NC siRNA)
was used as a negative control. Western blotting analysis
revealed that ALK protein was reduced in ALK siRNA
transfected cells but not in NC siRNA samples (Additional
file 1A). Similarly, MET specific knock-down was obtained
only in MET siRNA-transfecting cells (Additional file 1B).
Phosphorylated and total levels of AKT and ERK kinases
were not significantly modified by ALK or MET siRNA at
48 h after transfection (Additional file 1A and B). MET
(See figure on previous page.)
Fig. 2 Effects of crizotinib on cell proliferation and morphology of RH4 and RH30 cell lines. a RH4 and RH30 cells were incubated for 72 h with
crizotinib at the indicated concentrations. The MTT assay was performed to assess relative cell numbers, which were plotted as a percentage of
cell viability calculated with respect to control cells treated with DMSO alone (0 μM considered at 100 %). Each point is the mean of nine replicate wells ±
standard deviation (SD) and is representative of three independent experiments. b RH4 and RH30 were plated on 12-well plates and treated with 1.5 μM
crizotinib for 72 h. Control represents DMSO-treated cells. Viable cells were counted by trypan blue exclusion staining and each bar represents the mean
value of three independent experiments ± SD. Statistical significance: **, p< 0.01. c Flow cytometry data represented as histograms showing percentages
of cells in G0/G1, S and G2/M phases in RH4 and RH30 cells after treatment with 1.5 μM crizotinib for 48 h. Control cells received DMSO at the same
concentration. Data are average values of three independent experiments. d Giemsa staining showing morphologic changes observed in RH4 and RH30
after 48 h of treatment with 1.5 μM crizotinib or mocked control. Cellular morphology was analysed under light microscope at 40× magnification.
e Immunofluorescence analyses showing the effect of crizotinib on microtubule dynamics. Normal bipolar spindle formation was altered in
RH4 and RH30 cells treated for 24 h with crizotinib. Cells were stained for tubulin (red) and DNA (blue). Nocodazole was used as positive control for
microtubule depolymerisation. Control cells were treated with DMSO. f Western blot analyses of a panel of cell cycle regulatory proteins in RH4 and
RH30 cells treated with 1.5 μM crizotinib (Crz). Control cells (Ctrl) were treated with DMSO. Tubulin expression was used as the internal control
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siRNA delivery was able to induce a modest G2/M arrest
in both RH4 (G2/M: 21.5 % MET siRNA vs. 13.3 % NC
siRNA) and RH30 (G2/M: 13.2 % MET siRNA vs. 9.1 %
NC siRNA) transfected cells, whilst ALK siRNA alone did
not significantly affect the percentage of cells in the G2/M
phase (12.4 % in ALK siRNA vs. 13.3 % in NC siRNA RH4
Fig. 3 Changes in molecular regulators of cell cycle in RH4 and RH30 cell lines treated with crizotinib. a Immunofluorescence experiments showing the
expression and localization of p21, Cdc25C, Cdc2, Cyclin B1 and p-Cdc2 (Thr14/Tyr15) proteins in RH4 cells treated or not with 1.5 μM crizotinib for 24 h.
b Immunofluorescence experiments showing the expression and localization of p21, Cdc25C, Cdc2, Cyclin B1 and p-Cdc2 (Thr14/Tyr15) proteins in RH30
cells treated with 1.5 μM crizotinib for 24 h. Control cells were treated with DMSO. TRITC-phalloidin was used to mark F-actin filaments of
cellular cytoskeleton. Images captured under ApoTome microscope at 40× magnification
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cells; 8.0 % in ALK siRNA vs. 9.1 % in NC siRNA RH30
cells). When ARMS cells were transfected for 48 h with
ALK, MET or NC siRNA, apoptosis was respectively:
15.6, 14.1 and 12.0 % for RH4, and 14.8, 13.9 and 10.2 %
for RH30 cancer cells, respectively, showing that single
targeting of ALK or MET proteins did not produce
notable programmed cell death. These data suggest that
ALK and MET are not the sole targets of crizotinib alter-
ing ARMS cellular phenotype.
Crizotinib inhibits both IGF1-induced signalling and cell
growth in ARMS cell lines
Since IGF1R, a tyrosine kinase receptor constitutively
activated and highly expressed in ARMS cells, share
structural homologies [34] with ALK and MET proteins,
the possible role of crizotinib on IGF1R phosphorylation
was explored. Indeed, drug treatment markedly inhibited
p-IGF1R levels and the IGF1-mediated signal transduc-
tion pathway (Fig. 6c). After ligand stimulation by IGF1,
a strong increase of phosphorylated IGF1R (p-IGF1R)
levels was observed in both RH4 and RH30. Crizotinib
pre-treatment for 4 h efficiently inhibited the IGF1-
mediated stimulation of p-IGFIR with a parallel decrease
of the known downstream effector p-AKT in both
ARMS cell lines, without the respective total protein
levels being perturbed (Fig. 6c). Crizotinib was also able
to block the IGF1-induced cell growth of RH4 and RH30
as shown by MTT cell proliferation assays (Fig. 6d). Cells
were starved and then allowed to grow for 48 h in the
presence of IGF1, with or without crizotinib. Crizotinib-
treated cells showed a decreased cell proliferation in
starved conditions and in the presence of IGF1 compared
with crizotinib-untreated cells (Fig. 6d). The present
findings show for the first time that crizotinib may also
act on IGF1R activity, thus circumventing possible
resistance mechanisms driven by IGF1R signalling ob-
served in RMS tumours.
Discussion
Recent clinical studies have reported a promising thera-
peutic impact of crizotinib, an ATP-competitive inhibitor
of ALK/MET activity, in the treatment of ALK- and/or
MET-positive tumours [25, 35]. However, its antitumor
properties in RMS, the most common soft tissue sarcoma
in children [1, 2], have only recently been questioned [11].
The growing interest in the expression and oncogenic
activity of ALK in RMS [8, 10, 11] implies a possible thera-
peutic role of crizotinib in this malignancy. Accordingly,
the present study investigated the possible effects and mo-
lecular mechanisms of crizonitib on RH4 and RH30 hu-
man ARMS cell lines, which over-express ALK and MET
genes at mRNA and protein levels (Fig. 1). The crizotinib-
treated cells displayed a significant decrease in prolifera-
tion and viability at clinically relevant concentrations
(≤5 μM) [25]. Interestingly, the reduced cell growth in
both tumour cell lines was primarily associated with cell
cycle arrest and apoptosis/autophagy, in accordance with
a very recently published article by Peron et al. [11]. This
study highlighted that after crizotinib exposure, RH4 and
RH30 cells accumulated in G2/M phase and showed mor-
phological alterations, such as enlarged or multiple nuclei,
characteristic of defective cell division (Fig. 2c-d), which
was attributable to the deregulation of important cell cycle
regulators. In particular, crizotinib treatment led to the
down-regulation of Cyclin D3 expression and to the over-
expression of p21/p27 proteins. To this regard, Cyclin D3
activity associated with CDK4 has been reported to be ne-
cessary for cell cycle progression through G2 phase into
mitosis after UV radiation [36]. More specifically, crizotinib
caused cytoplasmatic retention of Cdc25C protein and
concomitant hyper-phosphorylation of Cdc2 at Thr14/
Tyr15, while Cyclin B1 became overexpressed and pre-
dominantly accumulated around the nuclear envelope.
Taken together, these data suggest that crizotinib activates
the G2/M checkpoint in ARMS cells by sequestering
Cdc25C in the cytoplasm and thus promoting the phos-
phorylation of Cdc2, which is not able to form an active
complex with Cyclin B1, this preventing the entrance in
the nucleus and so stalling the mitosis as reported in other
cancers [37, 38]. Furthermore, cell cycle perturbation
might also be related to the crizotinib ability of altering cel-
lular microtubule dynamics, as revealed by the formation
of multipolar spindles (Fig. 2e).
The biological mechanisms altered by crizotinib also
include the modulation of signal transduction molecules
linked to the ALK/MET system, such as AKT and ERK,
which are involved in cell proliferation, adhesion, motil-
ity, differentiation and survival [39–41]. In both ARMS
(See figure on previous page.)
Fig. 4 Effects of crizotinib treatment on apoptosis in RH4 and RH30 cell lines. a Dot blot graphs show the rate of apoptosis in control and crizotinib-
treated cells (1.5 μM and 5 μM) for 48 h. Control cells were treated with DMSO at the maximum amount used to deliver crizotinib. Cells were stained
with Annexin V and 7-AAD followed by FACS analysis. The percentage of early and late apoptotic cells is indicated. b Apoptotic/necrotic cells in RH4
and RH30 increased in concomitance of increasing doses of crizotinib (1.5 and 5 μM), as demonstrated by Annexin V and PI staining. Cells
were observed and photographed under ApoTome fluorescence microscope. Control cells were treated with DMSO. c Caspase 3/7 activity is
induced in a dose-dependent manner in cells treated with crizotinib for 48 h. Control cells (Ctrl) were treated with DMSO. Histograms represent the mean
value ± SD of three independent experiments, each performed in triplicate (*, p<0.05; **, p<0.01). d Cleavage of PARP and caspase-3 was
evaluated by Western blotting experiments in RH4 and RH30 cells, treated with crizotinib (Crz) as indicated. Control cells (Ctrl) received
DMSO vehicle
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Fig. 6 Effects of crizotinib on ALK/MET phosphorylation, AKT and ERK activation and cell growth through IGF-1 signalling in RH4 and RH30 cell
lines. a Immunoprecipitation and western blot showing expression of p-ALK, total ALK and p-MET and total MET in RH4 and RH30 cells treated
with or without 1.5 μM crizotinib (Crz) for 24 h. Control cells (Ctrl) were treated with DMSO alone. b Western blotting analysis of phosphorylation
levels of AKT and ERK proteins and downstream molecules GSKβ and P70S6K in RH4 and RH30 cells treated with or without 1.5 μM crizotinib (Crz) for
24 h. Control cells (Ctrl) were treated with DMSO alone. c Western blotting analysis of phosphorylation levels of IGF1R and AKT proteins in IGF1-treated
cells with or without crizotinib. RH4 and RH30 cells were starved in serum deficient medium for 24 h prior to induce with IGF1 (50 ng/ml) for 30 min.
Crizotinib (1.5 μM) was added 4 h before ligand stimulation. d MTT proliferation assay in ARMS cells grown in the presence or absence of IGF1 (50 ng/ml)
and crizotinib (1.5 μM) for 48 h. Bars represent the mean values for nine replicate wells ± SD and are representative of three independent experiments
(See figure on previous page.)
Fig. 5 Effects of crizotinib treatment on autophagy, migration, invasion and colony formation in RH4 and RH30 cell lines. a Acridine orange
staining showed that RH4 and RH30 DMSO-treated control cells exhibited no autophagosomes, whereas crizotinib-treated cells showed abundant
cytoplasmic acidic vesicular organelles (AVO) formation, a characteristic of autophagy. Samples were observed under an ApoTome fluorescence
microscope. b LC3 and p62 protein levels were examined in RH4 and RH30 cells treated with crizotinib (Crz) at various concentrations for 24 h.
Control cells (Ctrl) received DMSO vehicle. c ARMS cells were treated with crizotinib (1.5 and 5 μM) for 24 h and H2DCFDA was added 45 min before
collecting cells. H2DCFDA fluorescent intensities were analysed by FACSCalibur. Control cells (Ctrl) with H2DCDA staining were used as a negative
control. Bar charts represent the mean fluorescence ± SD for each sample (*, p-value <0.05 compared with the respective negative control; **, p < 0.01).
Three independent experiments were performed. d Crizotinib (1.5 μM) treatment led to a decreased cell migration in both RH4 and RH30 cells.
Representative images of migrated cells using the transwell migration assay (crystal violet staining, magnification of 20×). Histograms represent
the average values ± SD as determined by counting 8 fields of cells under the microscope. Three independent experiments were performed,
each in triplicate (*, p-value <0.05 compared with the respective negative control; **, p< 0.01). Control cells were treated with DMSO. e Crizotinib (1.5 μM)
treatment led to decreased cell invasion in both RH4 and RH30 cells. Control cells were treated with DMSO alone. Representative images of invasive cells
using the Matrigel-invasion assay (crystal violet staining, 20× magnification). Histograms represent the mean value ± SD as determined by counting 8 fields
of cells under the microscope. Three independent experiments were performed, each in triplicate (*, p< 0.05). f Crizotinib (1.5 μM) induction led to a
decreased cell colony formation capacity in both RH4 and RH30 cells. Control cells were treated with DMSO alone. Representative images of a single cell
derived-sphere in mocked control and treated cells cultured in soft agar for 21 days (original 40× magnification)
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cell lines, crizotinib (at 1.5 μM) reduced ALK and MET
activation and caused a significant reduction in the
phosphorylation levels of AKT (Ser473), even if it was
less effective in suppressing ERK activation. The marked
inhibitory effect on p-AKT expression might explain the
profound alterations in cell proliferation and migration/
invasion observed in these experiments, as suggested by
the critical role of the PI3K/AKT/mTOR cascade in
DNA synthesis, G2/M transition [42–44] and invasion
of RMS cells [45]. The minor effect on ERK phosphoryl-
ation would explain why crizotinib is less effective in
inducing caspase-dependent apoptosis in RH4 and RH30
cells. These findings are consistent with previous studies
[46, 47] showing that a massive and concomitant block
of both PI3K/AKT/mTOR and RAS/MEK/ERK cascades
induces significant cytotoxicity in RMS cell lines, while
the individual inhibition of each pathway is not sufficient
to trigger apoptosis. Indeed, 1.5 μM concentration of
crizotinib moderately increased programmed cell death,
which dramatically enhanced only at higher concentra-
tions (i.e., 5 μM) as demonstrated by the typical
apoptotic morphology, increased early/late apoptotic cell
population and activation of PARP and caspase-3 in both
RH4 and RH30 (Fig. 4). Notwithstanding, high dose of
crizotinib led to an increased autophagic flux, as demon-
strated by autophagosome formation, augmented accu-
mulation of LC3-II and diminished levels of p62, this
proving the existence of an alternative death mechanism
by which this compound exerts its antitumor effects on
RMS cells. Indeed, the role of autophagy in accelerating
cell death seems to be context-dependent and recent lit-
erature reports situations where autophagy is related to
cytotoxic effects and senescence in cancer cells [48, 49].
Furthermore, as for many other anticancer agents [50, 51],
the excessive generation of ROS seems to be the mechan-
ism involved in the cytotoxic activity of crizotinib, with
endogenous ROS levels proportionally increasing with
the drug concentration (Fig. 5c). Thus, crizotinib ap-
pears to have multiple outcomes depending on the
tumour cell type or treatment conditions, such as dose-
concentrations. Surprisingly, ALK and MET silencing
by RNAi did not produce notable cell-cycle arrest or
apoptosis, indicating that crizotinib exposure is more
effective in blocking ALK and MET signalling than sin-
gle siRNA transfection. Even if the modest effect on cell
cycle and survival in RH4 and RH30 cells might be also
due to fact that we performed siRNA transient transfec-
tion, new evidences suggest that crizotinib may have
unidentified off-target antitumor effects which, inde-
pendently of ALK and/or MET, might contribute to the
cellular and molecular alterations observed in ARMS
cells [11, 52]. Indeed, non-MET related effects of crizo-
tinib were reported to contribute to the cell-cycle arrest
and cytotoxicity observed in thyroid cancer cells [52]
and inhibition of other RTKs, independently of ALK
expression and activity, was recently observed in RMS
cells [11]. To this concern, the present study found that
crizotinib was able to decrease phosphorylation levels
of intracellular IGF1R and cell proliferation in response
to IGF1 ligand stimulation (Fig. 6c), this suggesting that
the drug exerts negative effects on IGF1R signalling
system. The IGF1/IGF1R axis is overexpressed and con-
stitutively phosphorylated especially in PAX3/7-FOXO1
positive ARMS cells, this being one of the major
tumorigenic pathways in this tumour [53–55]. Whether
crizotinib inhibits IGF1R directly by binding to the cell
surface receptor or indirectly by a possible functional
interaction between ALK and IGF1R is an area of
current research. Indeed, common activation and regu-
latory mechanisms are believed to exist for members of
the RTK superfamily, comprehending ALK, MET and
IGF1R proteins [34], most likely due to their similar
nature. Likewise, recent data have shown that IGF1R
tyrosine kinase and the NPM-ALK oncogene associate
and reciprocally increase their phosphorylation and ac-
tivation to induce survival of T-cell ALK-positive ana-
plastic large-cell lymphoma cells [56, 57]. In line with
these observations, IGF1R, as well as MET and EGFR,
sensitivity to ALK inhibitors has just been demon-
strated by Peron et al. [11].
Collectively, our data show that crizotinib-dependent
induction of the G2/M checkpoint significantly contrib-
utes to the in vitro reduction of growth, survival and clo-
nogenicity of RH4 and RH30 cells. Even if crizotinib was
initially reported as an ALK and MET inhibitor, this
study support the evidence that this drug may exert its
effects by also affecting the activity of other RTKs show-
ing structural analogies in some of their domains, such
as IGF1R, and so a broader pool of downstream molecu-
lar targets [52]. Future studies will be needed to better
understand these additional signalling pathways and the
interplay among cascade components as well as to moni-
tor the in vivo crizotinib effects on RMS growth. The
current treatment for RMS is a combination of surgery,
chemotherapy and radiotherapy. However, the develop-
ment of resistance to chemotherapy and radiotherapy is
often a significant limiting factor, leading to therapeutic
failures and poor survival [58]. As previous studies sug-
gested that the inhibition of ALK and IGF1R pathways
may potentiate chemotherapy and radiotherapy in lung
cancer [59, 60], crizotinib might be an effective additional
therapeutic agent in patients with aggressive ARMS
tumours that overexpress ALK, MET and IGF1R proteins.
Conclusions
The exposure to crizotinib causes the individual or syner-
gistic ALK, MET and IGF1R inhibition, and thereafter
results in the down-regulation of AKT signal pathway,
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which eventually leads to the cell cycle arrest, inhibition of
migration/invasion and induction of apoptosis observed in
ARMS cell lines.
Additional file
Additional file 1: ALK and MET knock-down by RNA interference.
A: RH4 and RH30 cells were transfected with either scramble control siRNA
(NC siRNA) or ALK siRNA. Cells were harvested 48 h after transfection and
ALK, AKT (phosphorylated and total protein) and ERK (phosphorylated and
total protein) levels were analysed by Western blotting. B: RH4 and RH30
cells were transfected with either scramble negative control siRNA (NC siRNA)
or MET siRNA. Cells were harvested 48 h after transfection and MET,
AKT (phosphorylated and total protein) and ERK (phosphorylated and
total protein) levels were analysed by Western blotting. Tubulin was
used as loading control in all experiments. (TIFF 258 kb)
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